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Together with sanitation, vaccination is one of the most effective life-saving interventions available
in the fight against infectious diseases. As you read this issue of Frontier in Microbiology, scientists
around the globe are working toward developing vaccines against diverse infectious diseases,
allergies, cancer and autoimmune diseases. We believe that every major disease will eventually have
its vaccine. However, if we consider major infectious agents, such as human immunodeficiency
virus (HIV), hepatitis C virus (HCV), and Malaria, despite many years of effort, billions of dollars
spent and countless animal lives sacrificed, no vaccine is available to protect against these infections.
How did this happen? What prevents us from being victorious? In this issue of Frontier in
Microbiology, we examine why some of these vaccines have failed, collecting reflections from
leading researchers in the field.
Some of the key obstacles to vaccine development discussed in this issue include:
1. The genetic diversity of the target pathogen. In RNA viruses such as HIV and HCV, the error
prone RNA dependent polymerase generates quasispecies (Chanzu and Ondondo, 2014; John
and Gaudieri, 2014; Ondondo, 2014). In addition, influenza vaccines need to be reformulated
annually, due to antigenic drift (Quinones-Parra et al., 2014). Over half a century of malaria
vaccine development, despite awareness of the diversity of natural parasite populations, vaccines
that have progressed to human clinical trials have only included a small fraction of the
polymorphisms present in endemic regions. In addition to increasing the complexity of the
immunogen, antigenic diversity of the organism in different geographic regions has major
implications for vaccine efficacy. In this issue, Alyssa Barry and Alicia Arnott discuss the
importance of population genetic studies in identifying functionally relevant polymorphisms,
and argue that molecular epidemiological surveys are necessary to ensure that the vaccine
strain corresponds to the local target parasite populations (Barry and Arnott, 2014). Targeting
conserved pathogen antigens may help to overcome diversity, although these regions are often
concealed and/or less accessible to immune effectors. Indeed, Chiu and colleagues herein showed
that antibody titers to PfRh5 correlated with protection against Plasmodium falciparum in
clinical trials in PNG (Chiu et al., 2014). Moreover, Quinones-Parra and colleagues also showed
that broadly neutralizing antibodies targeting conserved regions, which developed naturally
following the 2009 influenza pandemic, provide hints to the nature of the responses a successful
vaccine should elicit (Quinones-Parra et al., 2014). As an example of this strategy, Drummer
and colleagues proposed that the conserved regions within HCV E2, especially the residues
that interact with the virus co-receptor CD81 (Drummer, 2014), may represent an attractive
immunogen in a HCV vaccine.
Li et al. HIV/HCV and Malaria Vaccine Failure
2. The discrepancy between immunogenicity and protection.
As highlighted in this issue, although many HIV vaccine
candidates induce strong T and B cell responses in pre-clinical
and Phase-I trials, these responses have thus far failed to
correlate with protection in larger scale trials (Chanzu and
Ondondo, 2014). The current immunological readouts, such
as ELISPOT, intracellular cytokine staining or antibody levels
do not appear to be adequate measures that predict vaccine
success or failure. New strategies of clinical trial monitoring,
such as those depicting immunogenicity from a new angle,
or those that dissociate the effects of the vaccine vector from
vaccine antigen, may need to be developed and applied. These
could include analysis of the T and B cell immune repertoire
(Li et al., 2013), which might identify the clonotype response
to the vector independent of responses to the immunogen.
In addition, whole genome transcription arrays and other
recent high throughput assays are likely to provide new and
unexpected insights. Overall, new concepts are required to
define the best reference or readout of immunogenicity that
may in turn predict protective efficacy.
3. Vector or Immunogen, which one matters? While an
effective vaccine may need to be multivalent, comprising
multiple alleles for a given polymorphic antigen, and/or the
antigen derived from conserved regions, the delivery vectors
are at least as important as the immunogen itself. The vectors
modulate innate and adaptive immunity, hopefully enabling
the vaccine antigen to elicit the right response (Ondondo,
2014). Prime-boost strategies using plasmid DNA or viral
vector prime followed by protein or viral vector boost have
been studied extensively. An important lesson was learned
from the HIV STEP study, in which a highly immunogenic
vaccine actually increased HIV acquisition, presumably due
to preexisting immunity to the vector. Of the proposed
explanations, a strong response to the vector may have
activated CD4+ T cells, which are targets for HIV. This
seemingly unavoidable paradox highlights the challenges of
HIV vaccine development.
4. The discrepancy between local and systemic responses.
Rafferty and colleagues argue that of the vectors used in
HIV vaccine design, viral vectors with mucosal tropism,
e.g., adenoviruses and influenza viruses, are particularly
interesting, given that genitorectal mucosa is the first site
of contact in HIV transmission (Rafferty et al., 2014). Most
systemic vaccines do not elicit mucosal responses, and it is
uncertain if mucosal delivery of antigen can induce systemic
immunity. Cytokines and chemokines have been used as
adjuvants to encourage mucosal homing of immune effector
cells, such as the “prime-pull” approach in animal models
(Rafferty et al., 2014). Difficulties in studyingmucosal immune
responses, including low cell numbers, sample variation
and invasiveness of mucosal sampling means that mucosal
immune responses are often not examined in clinical trials,
as discussed in this issue (Chanzu and Ondondo, 2014).
This is an important area of future clinical trial monitoring
and is being addressed. An effective HIV vaccine strategy
may need to involve both systemic and mucosal approaches
simultaneously. Indeed, women in third world countries share
the major burden of HIV infection, and a vaccine that can
effectively elicit mucosal immune responses in the female
genital tract is more likely to protect women (Rafferty et al.,
2014).
5. Infant vaccination, how much do we know? On a global
scale, millions of infants receive around 20 vaccines during
the first year of life, but relatively few studies have examined
the development of immunity in this age group. The innate
immune system does not reach full capacity until the teenage
years, and as adaptive immunity in newborns is intrinsically
skewed to a Th2-type, the neonatal and infant immune
responses to many vaccines are suboptimal (Ndure and
Flanagan, 2014). In addition, the naïve immune repertoire’s
initial response to a vaccine, which may engage both vaccine
antigen-specific and non-specific T and B cells, promoted for
example by inflammation via the TNFR2 receptor (Wilson
et al., 2015), may play an important role in shaping the
repertoire toward subsequent unrelated pathogens. Indeed,
growing evidence suggests that vaccines can have heterologous
effects, affecting an individual’s subsequent responses to
unrelated pathogens or vaccines (Flanagan et al., 2011). As
vaccines which target major global diseases are eventually
likely to be included in childhood vaccination, it is important
to understand how vaccines modulate the naïve immune
system and the long-term impact of this intervention.
6. Immune subversion and immunosuppression. Malaria-
infected red blood cells have an amazing capacity to
induce FOXP3+ expression, a marker of highly suppressive
regulatory T cells (Treg), on co-cultured autologous T cells,
suggesting that widespread induction in vivo would not
require direct contact with the parasite (Scholzen et al., 2014).
In an exciting mechanistic insight, in this issue, Wykes and
colleagues further show a role for PD-1 in malaria-induced
loss of T cell function and/or apoptosis (Wykes et al., 2014).
While it is not feasible to directly predict viral epitopes
recognized by the T cell receptor, Moise and colleagues show
that the JanusMatrix algorithm can be applied to achieve
this by searching for virus-encoded human homologs, which
theoretically can be recognized by Treg (Moise et al., 2014).
We also propose that to design improved vaccines we need
to better understand how genetic factors such as HLA can
affect viral susceptibility. For example, in addition to HIV and
HCV which interfere with HLA expression in host immune
cells, could HLA intrinsically influence T cell repertoire
development before the selection step?
Regardless of the chances of developing a prophylactic vaccine
for every disease, the world needs vaccines to reduce current
disease burdens and save lives. How to effectively mobilize
innate immunity may be another focus for future vaccine design.
Learning from our mistakes and understanding our limitations
will help us in our ongoing battle against pathogens.
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